文献速递药物不良反应与药物警戒

成人经外周静脉持续输注3%氯化钠注射液与静脉炎的相关性

Association between continuous peripheral i.v. infusion of 3% sodium chloride injection and phlebitis in adults.
PubMed 文献 · Am J Health Syst Pharm · 2018-01-01

该研究在一家学术医疗中心开展为期13个月的前瞻性观察性质控项目,评估成人住院患者经专用外周静脉导管持续≥4小时输注3%氯化钠注射液与经另置外周静脉导管输注常规液体时的患者及导管静脉炎发生率。结果显示两组患者静脉炎(47% vs 43%,p=0.19)与导管静脉炎(30% vs 22%,p=0.16)均无显著差异,提示外周输注高渗盐水以900 mOsm/L为渗透压上限可能并不必要。

要点

  • 3%氯化钠经外周静脉持续输注≥4小时与常规液体相比,患者静脉炎和导管静脉炎发生率均无显著差异。
  • 患者静脉炎47% vs 43%(p=0.19),导管静脉炎30% vs 22%(p=0.16)。
  • 结果提示外周输注高渗盐水设900 mOsm/L渗透压上限可能缺乏依据。

核心结论

  • 3%氯化钠注射液经外周静脉持续输注与常规液体输注相比,患者静脉炎和导管静脉炎发生率无显著差异。
  • 作者认为外周输注高渗盐水的900 mOsm/L渗透压上限可能并不必要。

研究设计与样本

  • 前瞻性、观察性、为期13个月的质量保证项目,在学术医疗中心开展。
  • 纳入同一住院期间经专用外周静脉导管输注3%氯化钠≥4小时、并另经外周静脉导管输注常规液体的成人住院患者。

主要发现

  • 78%的患者因颅内高压接受3%氯化钠输注,30%在重症监护病房接受该输注。
  • 患者静脉炎:3%氯化钠输注期间28例(47%),常规液体输注期间26例(43%),p=0.19。
  • 导管静脉炎共73根(25%);3%氯化钠组30%(106根中32根)vs 常规液体组22%(185根中41根),p=0.16。

临床怎么用

  • 成人患者可经外周静脉导管以最高100 mL/hr的速率较长时间输注3%氯化钠注射液,并以专用导管给药。
  • 监测静脉炎发生,但不必仅因渗透压超过900 mOsm/L而拒绝外周输注高渗盐水。

局限性

  • 原文摘要未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: One institution's experience with use of peripheral i.v. (PIV) catheters for prolonged infusions of 3% sodium chloride injection at rates up to 100 mL/hr is described. METHODS: A prospective, observational, 13-month quality assurance project was conducted at an academic medical center to evaluate frequencies of patient and catheter phlebitis among adult inpatients who received both an infusion of 3% sodium chloride injection for a period of ≥4 hours through a dedicated PIV catheter and infusions of routine-care solutions (RCSs) through separate PIV catheters during the same hospital stay. RESULTS: Sixty patients received PIV infusions through a total of 291 catheters during the study period. The majority of patients (78%) received infusions of 3% sodium chloride injection for intracranial hypertension, with 30% receiving such infusions in the intensive care unit. Phlebitis occurred in 28 patients (47%) during infusions of 3% sodium chloride and 26 patients (43%) during RCS infusions (p = 0.19). Catheter phlebitis occurred in 73 catheters (25%), with no significant difference in the frequencies of catheter phlebitis with infusion of 3% sodium chloride versus RCSs (30% [32 of 106 catheters]) versus 22% [41 of 185 catheters]), p = 0.16). CONCLUSION: Patient and catheter phlebitis rates were not significantly different with infusions of 3% sodium chloride injection versus RCSs, suggesting that an osmolarity cutoff value of 900 mOsm/L for peripheral infusions of hypertonic saline solutions may not be warranted.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Meng L, Nguyen CM, Patel S, et al. Association between continuous peripheral i.v. infusion of 3% sodium chloride injection and phlebitis in adults. Am J Health Syst Pharm. 2018. PMID: 29472509. doi:10.2146/ajhp161028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。